On Invalid Date, Mirum Pharmaceuticals (NASDAQ: MIRM) reported Q2 2024 earnings per share (EPS) of -$0.52, up 73.2% year over year. Total Mirum Pharmaceuticals earnings for the quarter were -$24.64 million. In the same quarter last year, Mirum Pharmaceuticals's earnings per share (EPS) was -$1.94.
As of Q3 2024, Mirum Pharmaceuticals's earnings has grown year over year. Mirum Pharmaceuticals's earnings in the past year totalled -$109.16 million.
What is MIRM's earnings date?
Mirum Pharmaceuticals's earnings date is Invalid Date. Add MIRM to your watchlist to be reminded of MIRM's next earnings announcement.
What was MIRM's revenue last quarter?
On Invalid Date, Mirum Pharmaceuticals (NASDAQ: MIRM) reported Q2 2024 revenue of $77.88 million up 107.68% year over year. In the same quarter last year, Mirum Pharmaceuticals's revenue was $37.50 million.
What was MIRM's revenue growth in the past year?
As of Q3 2024, Mirum Pharmaceuticals's revenue has grown 128.34% year over year. This is 51.46 percentage points higher than the US Biotechnology industry revenue growth rate of 76.88%. Mirum Pharmaceuticals's revenue in the past year totalled $264.38 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.